Atlas Trials

Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy

Clinical trial NCT00859001 · COMPLETED

Trial details

NCT number
NCT00859001
Sponsor
University of Bologna
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Follicular Lymphoma
Enrollment
55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.